Guselkumab (TREMFYA (R)) provides consistent and durable pain improvement in patients with active psoriatic arthritis: results of 2 phase 3, randomized, controlled clinical trials

No Thumbnail Available
File version
Author(s)
Nash, Peter
Tam, Lai-Shan
Tsai, Wen-Chan
Leung, Ying-Ying
Furtner, Daniel
Sheng, Shihong
Wang, Yanli
Shawi, May
Kollmeier, Alexa
Sherlock, Jonathan
Cua, Daniel
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2021
Size
File type(s)
Location
License
Abstract

Background/Purpose: Guselkumab (GUS), a targeted inhibitor of IL-23p19, demonstrated significant efficacy v placebo (PBO) in achieving ACR20 response at week (W) 24 in patients (pts) with active PsA in 2 Phase 3 trials, DISCOVER-1 & 2.1,2 Pts with PsA report pain relief as a priority for treatment.3 We conducted post hoc analyses to further assess GUS effect on pt-reported pain across outcome measures and maintenance of pain relief with up to 2 years (yr) of GUS. Methods: DISCOVER-1 (1 yr) included 381 pts with active PsA despite standard therapies, including 1-2 TNF inhibitors in 31% of pts. DISCOVER-2 (2 yr) included 739 biologic-naïve pts with active PsA. In both studies, pts were randomized (1:1:1) to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, then Q8W; or PBO with crossover to GUS 100 mg Q4W at W24 (PBO→Q4W). Pts rated pain using a 0-10 VAS (Pt Pain) as part of ACR, Disease Activity in Psoriatic Arthritis, and Minimal Disease Activity response criteria and reported Bodily Pain intensity over the past 4W via the 36-Item Short-Form Health Survey (SF-36) question 21 (0-5). Pts with spondylitis and peripheral arthritis at baseline (BL) rated their Spinal and Joint Pain (0-10) as part of BASDAI. Pain data were evaluated for observed mean change, percent improvement from BL, and proportion of pts achieving ≥20% or ≥50% improvement in Pt Pain (nonresponder imputation [NRI]). Percent improvement from BL in tender (TJC; 0-68) and swollen (SJC; 0-66) joint counts, determined by independent assessors, was determined to evaluate consistency of improvements in pt-reported v physician-derived pain measures. Results: In DISCOVER-2, mean BL Bodily Pain (range across groups: 4.4-4.5), Pt Pain (6.2-6.3), Spinal Pain (6.5-6.7), Joint Pain (6.3-6.8), SJC (11.7-12.9) & TJC (19.8-22.4) indicated moderate pain and disease activity at study outset. GUS-treated pts reported ~2x the improvement in Pt Pain, Spinal Pain, Joint Pain & Bodily Pain intensity at W24 v PBO; GUS improvements were maintained or further increased at W52 & W00. PBO→Q4W pts had similar improvements in pain as GUS-randomized pts (Table 1, Figure). Pt-reported pain appeared more sensitive to treatment effect, with larger differences in percent improvement v PBO, than physician-reported TJC/SJC at W24 (Figure); further research is warranted. While patterns were consistent, pain improved to a lesser degree than TJC/SJC, suggesting other causative factors. Consistent results were seen in DISCOVER-1 through 1 yr (data not shown). Among 748 GUS-treated pts across DISCOVER-1 & 2, substantial proportions achieved meaningful improvement in Pt Pain at early time points: 32% (W4) and 48% (W8) achieved ≥20% improvement; 28% (W12) and 33% (W16) achieved ≥50% improvement. At W24, 63% and 39% reported ≥20% and ≥50% pain improvement (Table 2). Conclusion: GUS provided consistent and durable improvements in pt-reported pain across several measures. Ptreported pain as an early and sensitive indicator of treatment effect in pts with active PsA and other factors underlying pain merit further evaluation.

Journal Title
Conference Title

Arthritis & Rheumatology

Book Title
Edition
Volume

73

Issue

S9

Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Rheumatology and arthritis

Immunology

Science & Technology

Life Sciences & Biomedicine

Rheumatology

double-blind

biologic-naive

Persistent link to this record
Citation

Nash, P; Tam, L-S; Tsai, W-C; Leung, Y-Y; Furtner, D; Sheng, S; Wang, Y; Shawi, M; Kollmeier, A; Sherlock, J; Cua, D, Guselkumab (TREMFYA (R)) provides consistent and durable pain improvement in patients with active psoriatic arthritis: results of 2 phase 3, randomized, controlled clinical trials, Arthritis & Rheumatology, 2021, 73, S9, pp. 2769-2772